No Data
10 trillion debt-for-equity swap, real estate tax policies will be introduced in the near future... One article to understand the NPC press conference
Starting from 2024, China will allocate 800 billion yuan from the annual increase in local government special bonds for five consecutive years, specifically for debt restructuring, with a cumulative potential to replace 4 trillion yuan in hidden debt. In addition, with the 6 trillion yuan debt ceiling approved by the National People's Congress Standing Committee this time, it will directly increase local debt resources by 10 trillion yuan.
Lu Chongmao: The "1+" mechanism has approved a total of 5 new drug applications, with the cost of 2 drugs decreasing by nearly 30%.
Dr. Constance Chan, Director of Health, stated at the Legislative Council meeting today (8th) that since the new drug approval mechanism ("1+1" mechanism) took effect, the Department of Health has received inquiries from more than 80 pharmaceutical companies, totaling over 260, and has approved a total of 5 new drug applications. These include 2 treatments for metastatic colorectal cancer, 1 treatment for paroxysmal nocturnal hemoglobinuria, 2 treatments for patients with parathyroid cancer and a certain type of hypercalcemia in patients with primary hyperparathyroidism. Dr. Constance Chan revealed that two of the new drugs for the treatment of metastatic colorectal cancer have been included in the public hospital authority's list of specialty drugs. The public hospital authority has also successfully completed procurement discussions.
Hong Kong stocks have seen unusual movements, with CRO concept stocks generally under pressure. The emotions are influenced by the results of the USA election. Institutions point out that the probability of the Biosecurity Law being an independent law may
CRO concept stocks are generally under pressure. As of the time of publication, GenScript Biotech (01548) fell by 6.68% to HKD 10.9; Viva Biotech (01873) fell by 3.16% to HKD 0.92; Pharmaron (03759) fell by 2.64% to HKD 16.22.
CICC: Maintains hutchmed (china) 'outperform' rating with a target price of HK$38.25.
CICC maintains hutchmed (china) (00013) 2024/2025 EPS forecast of -0.12 yuan/0.01 yuan.
hutchmed (china) (00013.HK): FRUZAQLA third quarter meets expectations ESLIM-01 data update
As of October 31st, the company's partner Takeda released the FY2024 Q2 (3Q24) financial report. Fruzaqla (Flutamide) 3Q24 sales amounted to 11.1 billion Japanese yen (approximately 0.072 billion US dollars).
Bocom Intl: The tenth batch of national procurement starts with reported volumes. Bullish on sector sentiment improvement + valuation recovery after medical insurance negotiations land.
bocom intl highly recommends akeso (09926), simcere pharma (02096), legend biotech (LEGN.US), silver crest new yaobin-B (01952), and hutchmed (china) (00013), etc.
No Data
No Data